Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hormas Ghadially

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Journal of Immunology (Baltimore, Md. : 1950)|February 8, 2019
Correction: High-Resolution Genetic and Phenotypic Analysis of KIR2DL1 Alleles and Their Association with Pre-EclampsiaOisín Huhn, Olympe Chazara, Martin A Ivarsson, et al.
Journal for Immunotherapy of Cancer|March 22, 2022
Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockadeEmmanuel C Patin, Magnus T Dillon, Pablo Nenclares, et al.
Cell|December 4, 2018
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK CellsPascale André, Caroline Denis, Caroline Soulas, et al.
Molecular Cancer Therapeutics|March 13, 2023
Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination PartnersAatman S Doshi, Susan Cantin, Marylens Hernandez, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Journal of Immunology (Baltimore, Md. : 1950)|February 8, 2019
Correction: High-Resolution Genetic and Phenotypic Analysis of KIR2DL1 Alleles and Their Association with Pre-EclampsiaOisín Huhn, Olympe Chazara, Martin A Ivarsson, et al.
Journal for Immunotherapy of Cancer|March 22, 2022
Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockadeEmmanuel C Patin, Magnus T Dillon, Pablo Nenclares, et al.
Cell|December 4, 2018
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK CellsPascale André, Caroline Denis, Caroline Soulas, et al.
Molecular Cancer Therapeutics|March 13, 2023
Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination PartnersAatman S Doshi, Susan Cantin, Marylens Hernandez, et al.
Pageof 3